» Articles » PMID: 22334513

Detection of Early Abl Kinase Activation After Ionizing Radiation by Using a Peptide Biosensor

Overview
Journal Chembiochem
Specialty Biochemistry
Date 2012 Feb 16
PMID 22334513
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The ubiquitously expressed Abl protein is a non-receptor tyrosine kinase that undergoes nuclear-cytoplasmic shuttling and is involved in many signaling pathways in the cell. Nuclear Abl is activated by DNA damage to regulate DNA repair, cell-cycle checkpoints and apoptosis. Previous studies have established that ataxia telangiectasia mutated (ATM) activates nuclear Abl by phosphorylating serine 465 (S465) in the kinase domain in response to ionizing radiation (IR). Using a peptide biosensor that specifically reports on the Abl kinase activity, we found that an Abl-S465A mutant, which is not capable of being activated by ATM through the canonical site, was still activated rapidly after IR. We established that DNA-dependent protein kinase (DNAPK) is likely to be responsible for a second pathway to activate Abl early on in the response to IR through phosphorylation at a site other than S465. Our findings show that nuclear and cytoplasmic Abl kinase is activated early on (within 5 min) in response to IR by both ATM and DNAPK, and that although one or the other of these kinases is required, either one is sufficient to activate Abl. These results support the concept of early Abl recruitment by both the ATM and the DNAPK pathways to regulate nuclear events triggered by DNA damage and potentially communicate them to proteins in the cytoplasm.

Citing Articles

Recent Advances in Biosensor Technology for Early-Stage Detection of Hepatocellular Carcinoma-Specific Biomarkers: An Overview.

Chinnappan R, Makhzoum T, Arai M, Hajja A, Abul Rub F, Alodhaibi I Diagnostics (Basel). 2024; 14(14).

PMID: 39061656 PMC: 11276200. DOI: 10.3390/diagnostics14141519.


A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity : A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias.

Montecchini O, Braidotti S, Franca R, Zudeh G, Boni C, Sorio C Front Pharmacol. 2021; 12:749361.

PMID: 34867354 PMC: 8640483. DOI: 10.3389/fphar.2021.749361.


Predicted Cellular Interactors of the Endogenous Retrovirus-K Integrase Enzyme.

Benoit I, Brownell S, Douville R Microorganisms. 2021; 9(7).

PMID: 34361946 PMC: 8303831. DOI: 10.3390/microorganisms9071509.


Quantitative Tyrosine Phosphoproteomic Analysis of Resistance to Radiotherapy in Nasopharyngeal Carcinoma Cells.

Shen L, Li Z, Shen L Cancer Manag Res. 2020; 12:12667-12678.

PMID: 33328764 PMC: 7733897. DOI: 10.2147/CMAR.S260028.


c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.

Deville S, Silva L, Vehlow A, Cordes N Int J Mol Sci. 2020; 21(19).

PMID: 33019757 PMC: 7583921. DOI: 10.3390/ijms21197277.


References
1.
Kharbanda S, Yuan Z, Weichselbaum R, Kufe D . Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene. 1999; 17(25):3309-18. DOI: 10.1038/sj.onc.1202571. View

2.
Shafman T, Khanna K, Kedar P, Spring K, Kozlov S, Yen T . Interaction between ATM protein and c-Abl in response to DNA damage. Nature. 1997; 387(6632):520-3. DOI: 10.1038/387520a0. View

3.
Khanna K, Jackson S . DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001; 27(3):247-54. DOI: 10.1038/85798. View

4.
Woodring P, Hunter T, Wang J . Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci. 2003; 116(Pt 13):2613-26. DOI: 10.1242/jcs.00622. View

5.
Mahowald G, Baron J, Mahowald M, Kulkarni S, Bredemeyer A, Bassing C . Aberrantly resolved RAG-mediated DNA breaks in Atm-deficient lymphocytes target chromosomal breakpoints in cis. Proc Natl Acad Sci U S A. 2009; 106(43):18339-44. PMC: 2775277. DOI: 10.1073/pnas.0902545106. View